Genmab A/S
Toldbodgade 33
1253 Copenhagen K
Denmark
Tel + 45 7020 2728
Fax + 45 7020 2729
CVR no. 2102 3884

Contact:

Helle Husted
Director, Investor Relations
T: +45 33 44 77 30
M: +45 25 27 47 13
E: hth@genmab.com

GENMAB ANNOUNCES EARLY RESULTS OF ONGOING HUMAX-CD4 TRIALS

Summary: Positive preliminary data from the HuMax-CD4 Phase III CTCL and Phase II NCTCL support further development.

Copenhagen, Denmark; December 10, 2006 – Genmab A/S (CSE: GEN) announced today positive early results of the first stage of the ongoing pivotal Phase III study of HuMax-CD4® (zanolimumab) in cutaneous T-cell lymphoma (CTCL) and the ongoing Phase II study in non-cutaneous T-cell lymphoma (NCTCL). In the pivotal CTCL study, clinical response was shown in 5 of 12 patients (42%) in the two highest dose groups. A partial response was obtained by 1 of 6 patients (16%) in the 8 mg/kg dose group and 4 of 6 patients (67%) in the 14 mg/kg dose group. Patients were also treated at the 4 mg/kg dose level, with no responses observed. This dose level is not being used in the second part of the ongoing pivotal study.

A total of 22 patients were enrolled in three dose cohorts in the first part of the pivotal study and received infusions of 4, 8, or 14 mg/kg of HuMax-CD4 once weekly for 12 weeks. Patients were evaluated 4 and 8 weeks after the final treatment dose and every 8 weeks until progression of disease. The goal of this first portion of the Phase III study was to characterize material obtained from a new manufacturing site.

"We have successfully characterized the new HuMax-CD4 material and have moved into the second phase of the CTCL pivotal study," said Lisa N. Drakeman, Ph. D., Chief Executive Officer of Genmab. "We are encouraged by the response rates in these patients who have failed other therapies."

Preliminary results in the ongoing Phase II clinical trial in HuMax-CD4 to treat non-cutaneous T-cell lymphoma (NCTCL) showed that 4 of 14 patients (28.5%) had objective responses. Plans are ongoing to next test HuMax-CD4 in combination with chemotherapy for the NCTCL patients.

Results from both studies will be presented at the 48th American Society of Hematology Annual Meeting and Exposition in Orlando, Florida December 9-12, 2006.

GENMAB ANNOUNCES EARLY RESULTS OF ONGOING HUMAX-CD4 TRIALS

The preliminary HuMax-CD4 CTCL Phase III results are being presented at poster session #2731 on December 10 from 9AM to 8PM local time in Hall E1, board 909. The preliminary NCTCL results are being presented in poster session #2723 on December 10, from 9AM to 8PM local time in Hall E1, board 901.

About CTCL and NCTCL
Cutaneous T-cell lymphomas are a group of lymphomas characterized by abnormal accumulation of malignant T-cells in the skin, potentially resulting in the development of rashes, plaques and tumors. The most common types of CTCL include mycosis fungoides (MF) and Sézary syndrome (SS). CTCL result from errors in the production of T-lymphocytes or transformation of T-lymphocytes into malignant cells. Abnormal, uncontrolled growth and multiplication of malignant T-lymphocytes result in accumulation of these lymphocytes in the skin and may in some cases spread and affect the lymph nodes and other body tissues and organs, resulting in life-threatening complications.

Non-cutaneous T-cell lymphomas (NCTCL) are defined by highly malignant disease, which has localized to the lymph nodes even at the earliest stage of the disease, and include angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma and unspecified peripheral T-cell lymphoma. NCTCL is characterized by aggressive progression with average survival time of approximately two years.

About HuMax-CD4 (zanolimumab)
HuMax-CD4 is a human monoclonal antibody currently in Phase III development for cutaneous T-cell lymphoma (CTCL) and in Phase II for non-cutaneous T-cell lymphoma. These types of lymphomas express the CD4 receptor, which is the target of HuMax-CD4. In April 2005, Genmab and the United States Food and Drug Administration (FDA) reached an agreement on the design of its pivotal study protocol for HuMax-CD4 to treat CTCL under the Special Protocol Assessment process (SPA). The pivotal study includes patients with MF who are refractory to or intolerant of Targretin® and one other standard therapy, and will treat a total of 88 patients.

In March 2004, Genmab announced that HuMax-CD4 had been designated a Fast Track Product by the US Food and Drug Administration (FDA). This designation covers patients with CTCL for whom no available therapy exists, i.e. have failed at least two systemic treatment regimens. HuMax-CD4 for the treatment of MF has also been granted Orphan Drug status in the US and Europe. HuMax-CD4 is being developed under a collaboration with Serono.

About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche

and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb® platform for the rapid creation and development of human antibodies to virtually any disease target. In addition, Genmab has developed UniBody™, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, Princeton, New Jersey, US and Hertfordshire in the United Kingdom. For more information about Genmab, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

###